COUGH SUPPRESSANT DRUGS MARKET ANALYSIS

Cough Suppressant Drugs Market, by Disease Type (Dry Cough and Wet Cough), by Drug Type (Dextromethorphan, Codeine, Noscapine, Butamirate, Benzonatate, Pholcodine, and Others), by Product Type (Over-the-counter (OTC) and Prescription Drug), by Age Group (Pediatric and Adult), by Dosage Form (Syrup, Tablet, and Others), by Distribution Channel (Hospital, Retail Pharmacy, Online Pharmacy, and Others), and Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Published In : Jan 2019
Code : CMI2427
Pages :175
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Cough Suppressant Drugs Market- Restraints

However, stringent regulations against the use of cough suppressant is expected to affect the global cough suppressant drugs market growth over the forecast period.

For instance, in February 2018, the Therapeutic Goods Administration reclassified codeine as prescription only medicine in Australia, which was previously available as over-the-counter medication. This reclassification was made, as regular use of medicines containing codeine may lead to its addiction.

In January 2018, the U.S. Food and Drug Administration made safety labeling changes to limit the use of codeine or hydrocodone containing prescription opioid cough and cold medicines in children younger than 18 years old to protect kids from serious risks of opioid ingredients containing cough treatment drugs. After the safety labeling changes, these products will no longer be indicated for treatment of cough in pediatric population and will be labeled for use only in adults aged 18 years and older.